Fresh analysis reveals that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle plans.
Research printed in a major health publication points out that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People buying these drugs need to be informed of the potential of fast rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to original mass in about one and a half years.
Analyzing Approaches
The analysis, which reviewed 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Researchers point out that individuals who shed pounds through diet and exercise usually see a less rapid creep back—around 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Nutrition scientists propose the mechanism of the injections explains the amplified weight return.
The injections copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating much more probable."
A Chronic Disease?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, considering the high risk of relapse, the therapy should be considered ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "highlight the persistent nature of obesity," similar to managing conditions like diabetes.
User Experiences
Users who have come off the jabs report a powerful return of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," said a patient.
The struggle is compounded if individuals have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are effective tools for weight loss, they are not a permanent fix and long-term success hinges on ongoing behavioural support.
